Index

Page numbers in italics refer to figures. Page numbers in bold denote entries in tables.

acculturation 456–457
parenting practices 457
Addiction Technology Transfer Centers (ATTCs) 179
adolescence, characteristics 285
adolescent community reinforcement approach (ACRA) 86, 108–109
adolescent domain of the developmental model 28–29
Adolescent Traditions Project 441
adolescent treatment models (ATM) 323
advocacy vacuum 483–487
African-American adolescents 33, 36
aggression in childhood 28
AIDS see HIV/AIDS and substance abuse
Al-Anon 44
alcohol
drinking patterns 143
minimum legal age for purchase 143
policy development 486
prevalence rates 82
alcohol use disorders (AUDs) 139
contingency management 381
alcoholics
offspring of alcoholics 35
genetic factors 34
Alcoholics Anonymous (AA) 44, 90
American Indian and Alaskan Native (AIAN) adolescents
communities 426–429
disruption 427
ecological framework 424
family-centered treatment 423–425, 437–443
inpatient treatment 429
perceived support systems 436
research
enhancement research 432–437
pilot research 431–432
substance use patterns 436
anticonvulsants 244
antisocial behavior, cognitive-behavioral therapy 405
anxiety disorders 233, 244, 269
attention deficit hyperactivity disorder (ADHD) 94, 235
atomoxetine 245, 253
autism spectrum disorders (ASD) 137
behavioral dysregulation 233
behavioral management approach 375, 388–390
behavioural treatment 41
binge drinking 79
biological domain of the developmental model 33–34
biological factors 137
blockading strategies 247
brief strategic family therapy (BSFT) 42, 86
British Crime Survey (BCS) 132
buffering model 34
economic identity as a protective factor 36
family factors as buffers 36–37
individual characteristics 35

Cambridge University Press
0521823587 - Adolescent Substance Abuse: Research and Clinical Advances
Edited by Howard A. Liddle and Cynthia L. Rowe
Index
More information
buprenorphine 39, 246
opioid dependency treatment 247
bupropion 245, 252, 274
nicotine addiction treatment 248
bupropion 244

Cannabis Youth Treatment (CYT) study 4, 104–105, 206, 401
field trials overview 110–111
trial 1 113–114
trial 2 114
findings highlights
common subtypes 111
co-occurring problems 111
improved treatment participation 112–113
positive therapist reaction to manualized treatment 115
problem recognition and low motivation 112
treatments reduced use and problems 113
implications and next steps 115–116
continuing care 117
future plans 120
high retention rates 116
manuals 119–120
mixed reactions 119
similar clinical outcomes 116–117
therapist acceptance of manualized therapies 117–118
therapist supervision level in community setting 118
treatments and rationale 105
adolescent community reinforcement approach (ACRA) 108–109
family support network (FSN) 107–108
MET/CBT5 105–106
MET/CBT12 106–107
multidimensional family therapy (MDFT) 109–110
care, context of 174–175
background 175–176
existing system 176–177
financing mechanisms and funding streams 181–184, 212, 214
optimal system 177–179
providers of care 179–181
recommendations 185–186
technology transfer and treatment quality 184–185
Center for Substance Abuse Treatment (CSAT) 2, 4, 105, 175
Charles and Helen Schwab Foundation 484
recommendations 484–485
child and adolescent mental health services (CAMHS) 193, 201
childhood domain of the developmental model 28

Children and Young People’s Unit (CYPU) 190
Children’s National Service Framework 191
cigarette smoking
cessation 248
contingency management 381
study procedure 382–384
study set-up 382
prevalence rates 82
clinical course following treatment 79–80, 96–98
relapse patterns
relapse process for adolescents 87–89
treatment outcome studies 80–87
special challenges
comorbidity 93–94
developmental transitions 96
neurocognitive factors 94–95
success-predicting factors
alternative pathways to success 91–93
personal/environmental characteristics 90–91
self-help group attendance 90
clinical perspectives on assessment of drug abuse 223
assessment model 223–224, 224
print resources 224–225
public access internet sites 225
bridging assessment and referral decisions 235, 235–236
client self-reporting 226
clinical implications 228–229
diagnostic interviews 226–227
questionnaires 227
timeline follow-back 227
validity 227–228
content variables 230
abuse and dependence diagnostic symptoms 231–232
clinical implications 234–235
coeexisting psychopathology 233–234
drug use history 230–231
educational status 233
family functioning and parenting practices 233
peer drug involvement 232–233
developmental considerations 225–226
future directions 236
non-self-reporting data 228
sources of information 229
archival records 230
clinical implications 230
parents 229
peers 229–230
cluster analysis procedures 362–364
coalition building 491
cognitive–behavioral skills training (CBST) 291
cognitive deficits 94
clinical perspectives on assessment of drug abuse 223
assessment model 223–224, 224
print resources 224–225
public access internet sites 225
bridging assessment and referral decisions 235, 235–236
client self-reporting 226
clinical implications 228–229
diagnostic interviews 226–227
questionnaires 227
timeline follow-back 227
validity 227–228
content variables 230
abuse and dependence diagnostic symptoms 231–232
clinical implications 234–235
coeexisting psychopathology 233–234
drug use history 230–231
educational status 233
family functioning and parenting practices 233
peer drug involvement 232–233
developmental considerations 225–226
future directions 236
non-self-reporting data 228
sources of information 229
archival records 230
clinical implications 230
parents 229
peers 229–230
cluster analysis procedures 362–364
coalition building 491
cognitive–behavioral skills training (CBST) 291
cognitive deficits 94
clinical perspectives on assessment of drug abuse 223
assessment model 223–224, 224
print resources 224–225
public access internet sites 225
bridging assessment and referral decisions 235, 235–236
client self-reporting 226
clinical implications 228–229
diagnostic interviews 226–227
questionnaires 227
timeline follow-back 227
validity 227–228
content variables 230
abuse and dependence diagnostic symptoms 231–232
clinical implications 234–235
coeexisting psychopathology 233–234
drug use history 230–231
educational status 233
family functioning and parenting practices 233
peer drug involvement 232–233
developmental considerations 225–226
future directions 236
non-self-reporting data 228
sources of information 229
archival records 230
clinical implications 230
parents 229
peers 229–230
cluster analysis procedures 362–364
coalition building 491
cognitive–behavioral skills training (CBST) 291
cognitive deficits 94
clinical perspectives on assessment of drug abuse 223
assessment model 223–224, 224
print resources 224–225
public access internet sites 225
bridging assessment and referral decisions 235, 235–236
client self-reporting 226
clinical implications 228–229
diagnostic interviews 226–227
questionnaires 227
timeline follow-back 227
validity 227–228
content variables 230
abuse and dependence diagnostic symptoms 231–232
clinical implications 234–235
coeexisting psychopathology 233–234
drug use history 230–231
educational status 233
family functioning and parenting practices 233
peer drug involvement 232–233
developmental considerations 225–226
future directions 236
non-self-reporting data 228
sources of information 229
archival records 230
clinical implications 230
parents 229
peers 229–230
cluster analysis procedures 362–364
coalition building 491
cognitive–behavioral skills training (CBST) 291
cognitive deficits 94
cognitive–behavioral therapy (CBT) 42, 86, 105–106, 106–107, 396
client–treatment matching 406–407
clinical trials for SUD treatment 398–402
common comorbid psychiatric disorders 402–403
anxiety disorders 404
conduct disorder/antisocial behavior 405
depression 403–404
post-traumatic stress disorder 404–405
future directions 411–412
group therapy 43
group versus individual intervention 407–408
mechanisms of change 408–411
underlying theoretical models 396–398
College on Problems of Drug Dependence (CPDD) 2
communication breakdown within families 425
communities
HIV/AIDS and substance abuse 296–298
large-group/community approaches to treatment 44
community reinforcement approach (CRA) 108, 209
comorbidity 93–94, 264–265, 276–278
clinical approach to integrating treatment of SUD and comorbidity 271–275
cognitive–behavioral therapy 402–403
developmental context and bidirectional impact 265–266
European studies 137–138
frequently occurring diagnoses 324
integrated clinical assessment 270–271
pharmacologic treatment of comorbid psychiatric disorders 248–250
role of psychiatric comorbidity 266–267
internalizing disorders 266–270
relationship of childhood psychiatric disorders to SUD 267–268
condom usage 293, 294, 302
females 300
males 300
conduct disorder (CD) 233, 249
cognitive–behavioral therapy 405
predictor of SUD 267
contextual predictors 287
control over external events as a protective factor 35
core team model SAP’s 338
cost of treatment services 211, 212
craving reduction 247
crime and drug use 192
Criminal/Juvenile Justice Treatment Networks (C/JJTN) 178
critical period hypothesis 409
cultural competence 450–452
culturally based treatment development in adolescent substance abuse 12–13
culturally informed family therapy for adolescents (CIFTA) 453
designing interventions 459–461
flexible design 461–462
draft manual 454
adolescent developmental literature 454–455
pilot cases 462–463
randomized trial testing of manualized model 464–465
curve-of-factors models 65
DARE program 487
depression 233, 249
cognitive–behavioral therapy 403–404
developmental context for intervention 44–45
adolescent domain 28–29
biological domain 33–35
childhood domain 28
ethnicity 32–33
family domain
marital relationship 30
parent-adolescent relationship 29–30
parental drug use and personality 30
implications for prevention and treatment 39–40
family treatment 41–42
group treatment 42–44
individual treatment 40–41
large-group/community approaches 44
interactions between individual, family, peer and environmental factors 34–35
environmental factors as buffers 37
ethnic identity as a protective factor 36
ethnic identity as enhancer of protective factors 37–38
familial factors as buffers 36–37
familial factors as enhancers of protective factors 38
individual characteristics as buffers 35
individual characteristics as enhancers of protective factors 37
peer factors as enhancers of protective factors 38
larger context 31–32
model 26–27
peer domain 31
dextroamphetamine 251
diagnostic interviews 226–227
diagnostic symptoms for abuse and dependence assessment 233–232
dissulfiram 39, 243
aversive therapy 247
divalproex 244
Drug Abuse Reporting Program (DARP) 150, 206, 316

treatment retention and outcomes 151–152

youth characteristics 149, 150

Drug Abuse Treatment Outcome Studies for Adolescents (DATOS-A) 81, 93, 155–156, 206, 317

changes in treatment profiles between TOPS and DATOS-A 160–161

program characteristics 156

outpatient drug-free programs 157

residential treatment programs 156–157

short-term inpatient programs 157

treatment outcomes 163–164

alcohol use 164

comorbid mental disorders 164–165

criminal activity 165

differences by ethnicity 165–166

differences by gender 166

drug use 164

HIV risk 165

types of service 161

youth characteristics 149, 157

changes in client characteristics 159–160

criminal involvement 159

demographic characteristics 157–158

drug use 158

mental disorders 158–159

drug action teams (DAT) 192

Drug Affinity Study 133

drug treatment principles 11

Early and Periodic Screening, Diagnosis and Treatment (EPSDT) mandates 181–182

Early Development Stages of Psychopathology (EDSP) study 133, 136

comorbidity and temporal sequence of disorders 137

educational status 233

efficiency of treatment provision 208–213

emotional dysregulation 233

empirically based interventions in adolescent substance abuse treatment 9–12

empirically supported treatments 476, 477

England, service organization and practice 189, 202

see also UK

Heath Advisory Service (HAS) 193–194

achievements 201–202

aims, objectives and principles 194

examples of service tiers 199–200

links with evidence 199–201

strategic framework 194–195

legal framework 189–190

recent UK policy initiatives 190–193

environment

environmental factors as buffers 37

treatment success predicting factors 90–91

ethnicity 32–33

see also American Indian and Alaskan Native adolescents, family-centered treatment; Hispanic adolescents, family-centered treatment

African-American adolescents 33, 36

differences in treatment outcomes 163–166

ethnic identity as a protective factor 36

ethnic identity as an enhancer protective factor 37–38

Europe

alcohol

drinking patterns 143

minimum legal age for purchase 143

comorbidity and temporal sequence of disorders 137–138

epidemiological trends and clinical implications 129–130, 137, 142–144

acute drug-related deaths 129

Germany 141–142

risk factors 138

main target areas of EU drug strategy 140

coordination 140

information 140

international collaboration 140

reduction of demand 140

reduction of supply 140

political implications of adolescent substance abuse 139–141

prevalence of substance use 130

across Europe 130–132

Austria 133–134

Finland 134–135

Germany 133

Switzerland 134

UK 132

prevalence of substance use and dependence 134–137

Finland 136–137

Germany 136

Netherlands 135–136

Spain 135–136

research initiatives 5

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 131

European Schools Project on Alcohol and other Drugs (ESPAD) 130, 131

expulsions from schools 191

externalizing behavior 456–457

factor-of-curves models 65, 66

families of adolescent substance abusers

see also American Indian and Alaskan Native adolescents, family-centered treatment;
Hispanic adolescents, family-centered treatment 36–37
familial factors as buffers 36–37
parental monitoring 36
familial factors as enhancers of protective factors 38
family interventions 357–359, 369–370, 399, 401
cluster analysis procedures 362–364
differences in individual outcomes 360–362
family profiles of change 366–367
implications for treatment 368
individual profiles of change 364
marijuana drug use profiles 365
patterns of change 359–360
predictors of profiles 365
family relationships 425
family functioning and parenting practices 232
parents as information sources for drug abuse assessment 229
role in therapeutic communities 320–321, 327
family therapies 327, 328
family treatment 41–42
HIV/AIDS and substance abuse 295–296
parent–adolescent relationship 29–30
immigration-related experiences 457–458
mutual attachment 29
parental discipline 29
parental drug use 30
parental monitoring 36
parent–child relationship 26, 425
parent-focused engagement intervention 401
familium 32, 458–459
family behaviour therapy (FBT) 85
family check-up 433, 434
family support network (FSN) 86, 107–108
fathers, protective characteristics 38
females
HIV/AIDS and substance abuse 299
intent to use condoms 300
protective factors 35
financing mechanisms and funding streams for care provision 183–184, 212, 214
federal support 213
seeking more funding 494
Finland
prevalence of substance use 134–135
prevalence of substance use and dependence 136–137
fishbowl procedure 380
fluoxetine 243, 230, 274
full information maximum likelihood methods 65–66
functional family therapy (FFT) 42, 86
future developments and challenges in adolescent SUD treatment 13–14, 473–476
policy as link between research and practice 494–495
policy work 479–480
advocacy真空 483–487
coalition building 491
creating policy plans 481–483
fact finding 490–491
funding 494
links to other initiatives 492–493
recommendations 487–490
reviewing existing policies 480–481
strategic planning 492
training of next generation 493
remaining gaps 476–478
using science to improve practice 478–479
gabapentin 244
gateway substances 226
gender differences in treatment outcomes 166
general growth mixture modeling (GGMM) framework 70
genetic vulnerability 33
Germany
clinical implications of substance use 141–142
treatment 144
prevalence of substance use 133
prevalence of substance use and dependence 136
group therapies 42–44
comparison with individual intervention 407–408
HIV/AIDS and substance abuse 291–292
effectiveness 292–294
limitations 294–295
large-group/community approaches 44
growth mixture modeling 70–72, 73
Health Behaviour in School-aged Children (HBSC) 131
Health Maintenance Organization (HMO) 403
health service research 204–206
ideal features 205–206
effective 206–208
efficient 209–213
equitable 213–214
patient-centered 208–209
redesigned 214–215
timing 209
Health Survey for England 132
health values as a protective factor 35
Health Advisory Service (HAS) 193–194
achievements 201–202
aims, objectives and principles 194
examples of service tiers 199–208
links between tiers 198–199
links with evidence 199–201
strategic framework 194–195
Heath Advisory Service (HAS) (cont.)
tier 1 193–196, 200
tier 2 196–197, 200
tier 3 197–198, 200
tier 4 198, 200
hierarchical clustering 362
Hispanic adolescents, family-centered
treatment 449
basic research and development 452–453
blending research and practice 465–466
empirically supported treatments 449–450
integrative family therapy 453–454
acculturation and parenting practices 457
basic research study 463–464
culture-related variables and processes 456–457
designing CIFTA interventions 459–461
draft manual from culturally informed model 454
family process and treatment 456
values and family processes 458–459
immigration-related experiences and parent-adolescent relationship 457–458
pilot cases to refine CIFTA model 459–461
shortcomings in achieving cultural competence 450–452
historical perspective on adolescent substance abuse treatment research 3–6
HIV/AIDS and substance abuse 284–286
creating policy plans 482–483
future directions 298–303
HIV risk and drug use 287–288
intervention levels 288–289
communities 296–298
families 295–296
individual HIV prevention counseling 289–290
small groups 291–292
hypophysal–pituitary–gonadal axis 286
hypothalamic–pituitary–adrenal axis 286
Indian Health Service (IHS) 426
individual characteristics
as enhancers of protective factors 37
treatment success predicting factors 90–91
individual cognitive problem-solving therapy (ICPS) 85
interpersonal factors 139
interpersonal group psychotherapy (IGP) 43
interrupted time series (ITS) models 61–63
intrapersonal factors 138
IQ as a protective factor 35
Join Together On-Line 207
k-means clustering 362, 363
latent growth curve model (LGCM) 370
latent variable growth modeling (LVGM) 32–53, 74
advantages 72–73
growth curve modeling 53–54
hierarchical or multilevel designs 64–65
full information maximum likelihood (FIML) methods 65–66
limited information multilevel latent growth modeling 67–69
incorporating missing data 73
integrated developmental model 55–56
interrupted time series (ITS) models 61–63, 63
limitations 74
modeling between-subjects effects 60–61
added growth models 61, 62
multivariate and higher-order extensions 59–60
multivariate extension 59
predictors and sequellae of change 58
sample size selection and power estimation 73–74
shape of growth over time 57–58
specification 56
intercept 56
slope 56–57
shortcomings in achieving cultural competence 450–452
shortcomings in achieving cultural competence 450–452
treatment audience profiling 69–70
growth mixture modeling 70–72, 71
two time point 57
typical approaches to studying change 54–55
Latino adolescents 32
learning disabilities 191
levo-alpha-acetylmethadol 246
lifetime timeline 270
limited information multilevel latent growth modeling 67–69
lithium 244
LoveLife program 297
males
HIV/AIDS and substance abuse 300
intent to use condoms 300
marijuana, prevalence rates 82
marital relationship of parents 30
MATCH project 85, 406
mechanism of drug reinforcement 378
Medicaid 182
medications 39
methadone 39, 243, 246
Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) study 266
methylphenidate 245, 251, 275
relapse following treatment (cont.)
survival rates 83
treatment outcome studies 80–87
religion and religiosity 31, 35, 431
research on adolescent substance abuse treatment
historical perspective 3–6
theoretical, empirical and methodological foundations 7
residential therapeutic community programs 44
residential treatment programs (RES) 156–157
RESPECT (HIV risk reduction project) 289, 290
respect for elders and authority 32, 458–459
reward pathway 378
risk factors 138, 358
interpersonal factors 139
intrapsychical factors 138
socio-environmental factors 138
substance-related factors 138
Robert Wood Johnson Foundation 175
Safer Choices program 292
schools
educational status 233
expulsions 191
truancy 191, 335
school-based treatments 334–336
effectiveness 336–337
future directions 347–350
mechanisms of change in group counseling 346–347
Student Assistance Program (SAP) 337–340
Teen Intervention Project
standardized Westchester model SAP 340–343, 
342, 343
study design and preliminary results 343–346
Schwab see Charles and Helen Schwab Foundation
search for contextual predictors 287
selective serotonin reuptake inhibitors (SSRIs) 243, 269
self-control as a protective factor 35
self-help groups 90
service costs 215, 212
Services Research Outcomes Study (SROS) 4
sexual behavior and drug use 287–288
Shadow Project 432
analysis of outcomes 434, 438
demographics 435
enhancement condition 433
evaluation model 432, 442
multilevel Adolescent Transitions Program strategy 441
seven-week protocol 424
traditional versus conventional services 439
smoking see cigarette smoking
social network analysis 301
Society for Adolescent Substance Abuse Treatment
Effectiveness (SASATE) 2
socioeconomic status (SES) 37
socioenvironmental factors 138
Spain, prevalence of substance use and dependence 135–136
staff turnover 210
staff-to-patient ratios 210
stage model 452
stage I 452
stage II 452
stage III 452
State Children’s Health Insurance Program (SCHIP) 183
stimulants: prevalence rates 82
strategic planning 492
Substance Abuse Block Grant 181, 182
Substance Abuse Prevention and Treatment Performance Partnership Block Grant (SAPTPPBG) 213
substance-related factors 138
Switzerland, prevalence of substance use 134
synergistic protective factors 35
systems of care 177
technology transfer in care provision 184–185
Teen Intervention Project
standardized Westchester model SAP 340–343, 342, 343
study design and preliminary results 343–346
therapeutic communities (TCs) for adolescents 313,
328–329
background and history 313–315
empirical basis 315–316
outcome studies 316–318
prototypical community 318–319
continuity of care/aftercare 321
role of family 320–321
treatment protocol 319–320
twenty-first century practice 321–323
client issues 324–325
clinical issues 323–324
methodological issues 323
policy issues 326–328
treatment issues 325–326
timeline follow-back 227
timing of treatment provision 209
tobacco cessation 248
training of next generation 493
Treating Adolescent Substance Abuse: State of the Science conference 1–2
treatment audience profiling 69–70
Treatment Improvement Protocols (TIPS) 107, 485
treatment outcome studies 148, 166–169
changes in treatment profiles between TOPS and DATOS-A 160–161
Drug Abuse Reporting Program (DARP) 150, 206, 316
treatment retention and outcomes 151–152
youth characteristics 149, 150
Drug Abuse Treatment Outcome Studies (DATOS-A)
155–156, 206, 317
program characteristics 156
treatment outcomes 163–164
youth characteristics 149, 157
Treatment Outcomes Prospective Study (TOPS)
130, 152, 206, 317
in-treatment services 131, 153
treatment retention and outcomes 153–155
youth characteristics 149, 152–153
treatment processes 161–162
motivation and engagement 162
retention 163
services received 162–163
treatments
group treatment 42–44
individual treatment 41
quality of care 184–185
truancy from schools 191, 335
UK
see also England, service organization and practice
prevalence of substance use 132
recent policy initiatives 190–193
research initiatives 5
unconventional personality traits in adolescence 29, 31
variable magnitude of reinforcement procedure 380, 384
victims of violence 31
voucher-based reinforcement therapy (VBRT) 379
Westchester model student assistance program 338, 339, 342, 343
standardization 340–343
study design and preliminary results 345–346
assessment/referral-only (AR) subjects 343, 344, 345

group counseling subjects 343, 344, 345
Western American Indian Treatment (WAIT) Center 429, 439
withdrawal treatment 246
young people, proportion of world population 284
Youth Justice Board for England and Wales 192
Youth Lifestyles Survey 132
youth offending teams (YOT) 192